

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

FOREST LABORATORIES, LLC and	)	
FOREST LABORATORIES	)	
HOLDINGS, LTD.,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	Civ. No. 14-1119-SLR
	)	
SIGMAPHARM LABORATORIES, LLC,	)	
et al.,	)	
	)	
Defendants.	)	

**ORDER**

At Wilmington this 30<sup>th</sup> day of June, 2017, for the reasons stated in the court’s opinion issued this same date;

IT IS ORDERED that judgment of validity of U.S. Patent 5,763,476 (“the ‘476 patent”) shall be entered in favor of plaintiffs Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd. (collectively, “plaintiffs”) and against all defendants in the consolidated action.


IT IS FURTHER ORDERED that, as to infringement of the asserted claims of the ‘476 patent:

1. By stipulation, judgment of infringement of claims 1, 2, 5 and 6 of the ‘476 patent shall be entered in favor of plaintiffs and against all defendants save for Sigmapharm.

2. By stipulation, judgment of infringement of claims 4, 9, and 10 shall be entered in favor of plaintiffs and against the Amneal and Hikma defendants.

3. Judgment of non-infringement of claims 4, 9, and 10 shall be entered in favor of the Alembic and Breckenridge defendants and against plaintiffs.

IT IS FURTHER ORDERED that, because the issue of infringement has been stayed as to defendant Sigmapharm Laboratories, LLC, the parties shall inform the court, on or before **July 7, 2017**, whether judgment should be entered in the consolidated case (the parties shall further submit an agreed upon form of judgment to that effect) or in the individual cases.

  
\_\_\_\_\_  
Senior United States District Judge